Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00494195 |
|
Recruitment Status :
Completed
First Posted : June 29, 2007
Last Update Posted : February 5, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Muscular Dystrophies | Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- First cohort Genetic: Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort | Phase 1 |
The primary objective of this study is the assessment of the safety of intramuscular administration to alpha-sarcoglycan deficient subjects of recombinant adeno-associated virus serotype 1 (rAAV1)-human alpha-sarcoglycan gene (hαSG) vector under control of a skeletal muscle creatine kinase promoter. The secondary objective is to determine the dose of rAAV1.tMCK.hαSG vector required to achieve a detectable level of alpha-sarcoglycan in muscle of subjects with this disorder.
A recombinant virus vector constructed from AAV1 has been altered to carry the human alpha-sarcoglycan gene expressed from a tMCK promoter. The construct has been shown to initiate the production of a functional alpha-sarcoglycan protein in laboratory animals. This construct can reverse the dystrophic phenotype in the alpha-sarcoglycan knock out mouse, a laboratory animal model for the clinical disorder. Intramuscular injection of rAAV1 restores muscle histology to normal and increases muscle strength to levels exceeding control knock out mice but not to the same degree as wild-type mice.
The proposed human clinical trial is a phase I, double-blind randomized protocol with injection of rAAV1.tMCK.hαSG gene vector into muscle. Two cohorts of subjects with LGMD2D(alpha-sarcoglycan deficiency), each with proven mutations will undergo gene transfer. A minimum of three subjects will be enrolled into each cohort. The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate considering the individual patient) with a dose of 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and 2 to 6 vector injections will be distributed in the direction of an X. The second cohort will receive the same dose delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo. On the day of the vector infusion, 4 hours before gene transfer, patients will receive intravenous methylprednisolone 2.0 mg/kg (not to exceed 1 gm total), with repeat doses on two consecutive mornings. The methylprednisolone is specifically given to diminish the immediate inflammation from the needle injection, which is known to arouse an inflammatory reaction and could contribute to bringing antigen presenting cells to the site of vector delivery. We have previously demonstrated that this treatment enhances gene expression by at least 2-fold (Included as part of BB-IND-12936 for minidystrophin gene transfer).
Safety endpoints to be assessed include inflammatory reaction to the vector, as evaluated by muscle biopsy, and changes in hematology, serum chemistry, urinalysis, immunologic responses to rAAV1 and alpha-sarcoglycan, and reported history and observations of symptoms. The patient will have 10 to 12 follow-up visits for the next 2 years after the initial infusion.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 6 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Phase I Gene Transfer of rAAV1.tMCK.Human-alpha-sarcoglycan for Limb Girdle Muscular Dystrophy Type 2D (LGMD2D) |
| Study Start Date : | March 2008 |
| Actual Primary Completion Date : | June 2011 |
| Actual Study Completion Date : | August 2011 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 1
The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and two to six vector injections will be distributed in the direction of an X. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
|
Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- First cohort
The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo. Other Name: LGMD2D Gene therapy-First cohort |
|
Experimental: 2
The second cohort will receive the same dose of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
|
Genetic: Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort
The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
Other Name: LGMD2D Gene therapy- Second cohort |
- Safety of AAV1.tMCK.human-alpha-sarcoglycan gene transfer via intramuscular injection to the EDB muscle [ Time Frame: Measured throughout the study ]
- Human-alpha-sarcoglycan gene expression at the site of gene transfer via muscle biopsy [ Time Frame: First cohort: Measured 45 days for two patients and at 90 days after gene transfer for one patient; Second cohort: Measured at 6 months after gene transfer for the three patients ]
- Muscle strength of the gene transferred muscle via maximal volume isometric contraction testing (MVICT) if selected muscle is suitable for strenght testing [ Time Frame: Measured 45 or 90 days after gene transfer in the first cohort, or 6 months post-gene transfer in second cohort depending on muscle biopsy date ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 5 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Six LGMD2D subjects ages 5 and older based on the clinical degree of involvement (impaired muscle function/weakness, sufficient muscle preservation)
- Preservation of EDB muscle or another muscle if judged more favorable because of adequate muscle mass for gene transfer
- Males and females of any ethnic group
- Established mutations of an -SG gene on both alleles
- Ability to cooperate for testing
- Sexually active patients must be willing to practice a reliable method of contraception during the study
Exclusion Criteria:
- Active viral infection (symptoms listed in section 9.0 of the protocol)
- LGMD2D subjects without weakness or functional loss
- Cardiomyopathy based on clinical exam and ECHO with ejection fraction less than 40%
- HIV infected
- Hepatitis A, B, or C infected
- Autoimmune diseases and immunosuppressive drugs (other than pulse methylprednisolone at time of gene transfer)
- Persistent leucopenia or leucocytosis (WBC less than or equal to 3.5 K/cu mm or at least 20.0 K/ cu mm) or neutrophils less than 1.5 K/ cu mm
- Concomitant illness or requirement for chronic drug treatment that in the opinion of the Principal Investigator creates unnecessary risks for gene transfer
- Pregnancy
- Abnormal laboratory values considered clinically significant
- Alcoholism (CAGE questionnaire), and laboratory tests such as GGT and MCV
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00494195
| United States, Ohio | |
| The Research Institute at Nationwide Children's Hospital | |
| Columbus, Ohio, United States, 43205 | |
| Principal Investigator: | Jerry R. Mendell, MD | The Research Institute at Nationwide Children's Hospital |
Publications of Results:
Other Publications:
| Responsible Party: | Jerry R. Mendell, Director, Center for Gene Therapy, Nationwide Children's Hospital |
| ClinicalTrials.gov Identifier: | NCT00494195 |
| Other Study ID Numbers: |
5U54AR050733 ( U.S. NIH Grant/Contract ) U54AR050733 ( U.S. NIH Grant/Contract ) 5U54AR050733 ( U.S. NIH Grant/Contract ) IRB07-00329 |
| First Posted: | June 29, 2007 Key Record Dates |
| Last Update Posted: | February 5, 2013 |
| Last Verified: | February 2013 |
|
limb girdle muscular dystrophy type 2D alpha-sarcoglycanopathy LGMD2D LGMD gene therapy gene transfer muscular dystrophy |
SGCA sarcoglycan limb girdle adeno-associated virus AAV AAV1 |
|
Muscular Dystrophies Muscular Dystrophies, Limb-Girdle Sarcoglycanopathies Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases |
Nervous System Diseases Genetic Diseases, Inborn Respiration Disorders Respiratory Tract Diseases Cardiomyopathies Heart Diseases Cardiovascular Diseases |